Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of rutaecarpine

A technology of rutaecarpine and rutaecarpa, applied in the field of medicine

Inactive Publication Date: 2017-04-26
ZUNYI MEDICAL UNIVERSITY
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Studies have shown that evodiamine has extensive cardioprotective effects, but there is no relevant report on the use of evodiamine in the preparation of drugs for the prevention or treatment of myocardial hypertrophy and / or cardiac hypertrophy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of rutaecarpine
  • Application of rutaecarpine
  • Application of rutaecarpine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0171] Application of evodiamine in the preparation of drugs for preventing or treating myocardial hypertrophy. The medicine is a tablet made by taking evodiamine as an active ingredient and adding pharmaceutical carriers or excipients. The tablet is prepared through the following steps: wet granulation and tabletting, according to parts by weight, mixing 1 part of evodiamine dry powder and 3 parts of starch, adding a soft material made of starch slurry with a mass fraction of 10%, The starch slurry contains citric acid with a mass fraction of 1%, so that it can be lightly gripped into agglomerates, lightly pressed to disperse, pass through a 16-mesh sieve to granulate, dry the wet granules at 40°C to 60°C, and granulate with a 16-mesh sieve , and adding 5% talcum powder with the mass of the prepared granule, mixing evenly, and directly compressing the tablet to obtain the product. Among them, Evodiaecarpine is prepared by the following steps: take Evodia rutaecarpa and crush...

Embodiment 2

[0173] Application of evodiamine in the preparation of drugs for preventing or treating myocardial hypertrophy. The medicine is a capsule prepared by taking evodiamine as an active ingredient and adding pharmaceutical carriers or excipients. The capsules are prepared by the following steps: take evodiamine dry powder and mix with soluble starch whose mass is 5 times that of the dry powder, pass through a 100-mesh sieve, and manually fill into No. 5 capsules.

[0174] Among them, Evodiaecarpine is prepared by the following steps: take Evodia rutaecarpa and crush it into a coarse powder, soak it in ethanol with a solid-to-liquid ratio of 3g:45mL for 5h, then extract it with 95% ethanol under reflux, and repeat twice; concentrate to obtain an extract, Fully dissolve the extract with a hydrochloric acid solution with a mass concentration of 3.5%, filter, adjust the pH of the filtrate to 9 with ammonia water, pass the filtrate through a cation exchange resin, elute with double dist...

Embodiment 3

[0176] Application of evodiamine in the preparation of drugs for preventing or treating myocardial hypertrophy and cardiac hypertrophy. Cardiac hypertrophy is the hypertrophy of cardiomyocytes induced by angiotensin II. Myocardial hypertrophy is hypertrophy of the heart muscle caused by narrowing of the abdominal aorta. The medicine is a granule prepared by taking evodiamine as an active ingredient and adding pharmaceutical carriers or excipients. The granules are prepared through the following steps: according to parts by weight, take 1 part of evodiamine dry powder, 3 parts of sucrose powder and 1.25 parts of dextrin, mix them evenly, add soft material made of 60% ethanol, and make it lightly hold into a ball , Gently press to disperse, pass through a 16-mesh sieve to granulate, dry at 60°C to 80°C, granulate with a 16-mesh sieve, and seal to obtain.

[0177] Among them, Evodiaecarpine is prepared by the following steps: take Evodia rutaecarpa and crush it into a coarse po...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of rutaecarpine to preparation of drugs used for preventing or treating myocardial hypertrophy and / or cardiac hypertrophy. Rutaecarpine can obviously inhibit cardiomyocyte hypertrophy induced by AngII and cardiac hypertrophy caused by coarctation of the aorta abdominalis. Through application of rutaecarpine, the diameters of myocardial cells treated by AngII can be obviously decreased; the protein contents of the myocardial cells are reduced; the expression of ANF mRNA is substantially decreased; and the content of NO and the activity of NOS obviously rise. The rutaecarpine allows the cardiac hypertrophy index of the ventriculus sinister to be obviously decreased, has similar effect like L-arg, obviously improves the morphological changes of cardiac muscle tissue and enables the expression of ANF mRNA to be obviously decreased.

Description

technical field [0001] The invention relates to an application of evodiamine, which specifically belongs to the technical field of medicine. Background technique [0002] The formation of cardiac hypertrophy is a relatively complex pathological process. Cardiac hypertrophy refers to the increase of myocardial mass (weight) at the organ and tissue level, and the increase of cardiomyocyte volume, weight and surface area at the cellular level, which is called cardiomyocyte hypertrophy. Because cardiomyocytes lose their ability to divide shortly after birth, the myocardium uses a hypertrophy compensatory mechanism to adapt to the needs of the body under the condition of long-term load increase after birth. Long-term continuous myocardial hypertrophy not only leads to changes in cardiomyocytes, but also Non-cardiomyocytes (fibroblasts, vascular smooth muscle cells, and endothelial cells) and extracellular matrix (mainly collagen fibers) also change, eventually causing the functio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/519A61P9/00C07D471/14
CPCA61K9/1652A61K9/2059A61K9/4866A61K31/519A61K36/754C07D471/14
Inventor 吴芹石京山陆远富张锋杨丹莉邓江
Owner ZUNYI MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com